FFA
ELVN icon

Farther Finance Advisors’s Enliven Therapeutics ELVN Stock Holding History

Farther Finance Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.8K Sell
780
-4
-0.5% -$218 ﹤0.01% 3686
2026
Q2 		$39.9K Sell
784
-26
-3% -$1.1K ﹤0.01% 3436
2026
Q1 		$30.6K Buy
810
+122
+18% +$3.38K ﹤0.01% 3354
2025
Q4 		$10.6K Buy
688
+682
+11,367% +$13.6K ﹤0.01% 3868
2025
Q3 		$123 Hold
6
– – ﹤0.01% 4803
2025
Q2 		$120 Hold
6
– – ﹤0.01% 4288
2025
Q1 		$113 Hold
6
– – ﹤0.01% 4054
2024
Q4 		$135 Hold
6
– – ﹤0.01% 3737
2024
Q3 		$153 Hold
6
– – ﹤0.01% 3706
2024
Q2 		$136 Hold
6
– – ﹤0.01% 3557
2024
Q1 		$113 Hold
6
– – ﹤0.01% 3361
2023
Q4 		$83 Buy
+6
New +$73 ﹤0.01% 3325

Other funds holding ELVN

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors's ELVN Position: Q3 2026 in Review

Farther Finance Advisors reduced its Enliven Therapeutics (ELVN) stake by 0.51% in Q3 2026, selling an estimated $218 and leaving 780 shares worth $35.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

Farther Finance Advisors first reported a position in ELVN in Q4 2023 and has held it in 12 quarters since. The position peaked at $39.9K in Q2 2026. 4 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Farther Finance Advisors held 780 shares of Enliven Therapeutics worth $35.8K as of Q3 2026.
  • Farther Finance Advisors sold 4 Enliven Therapeutics shares in Q3 2026, an estimated $218.
  • Enliven Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3686 holding.
  • Farther Finance Advisors first reported a position in Enliven Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Enliven Therapeutics position peaked at $39.9K in Q2 2026.
  • 4 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.